Skip to main content

Advertisement

SpringerLink
Log in

Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model

  • Paper
  • Published:
Prostate Cancer and Prostatic Diseases Submit manuscript

Abstract

In most clinical trials of intermittent androgen deprivation (IAD), the decision to stop androgen withdrawal is based on monitoring PSA levels, waiting for its drop to nadir. Based on in vitro pre-clinical studies, a modified ‘on–off’ schedule of short intervals of androgen deprivation, designated pulsed androgen deprivation (PAD), is proposed to destroy androgen dependent (AD) cells more gradually and to conserve their androgen-independent (AI) inhibitory potential for longer periods, resulting in an overall prolongation of time to hormone resistant progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA, USA

    AJ Pantuck, A Zismon, C-L Tso & AS Belldegrun

Authors
  1. AJ Pantuck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Zismon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C-L Tso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. AS Belldegrun
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pantuck, A., Zismon, A., Tso, CL. et al. Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model. Prostate Cancer Prostatic Dis 3, 280–282 (2000). https://doi.org/10.1038/sj.pcan.4500473

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500473

  • Springer Nature Limited

Keywords

Search

Navigation